The answer may just be a resounding 'yes!'
According to Medical Daily, medical researchers in Hadassah Medical Center in Jerusalem have produced some promising results from a clinical test of a vaccine they're calling ImMucin. The clinical test, which consisted of ten myeloma patients, produced some really promising results. Specifically, we're seeing results of an increased immune system response, which enabled the immune systems of the patients to help fight the cancer without the help of radiology.
"ImMucin generated a robust and specific immune response in all patients which was observed after only 2-4 doses of the vaccine out of a maximum of 12 doses. In some of the patients, preliminary signs of clinical efficacy were observed," said Vaxil Biotheraputics, the drug makers in charge of creating the vaccine.
The drug works by identifying cancerous cells, which have a higher concentration of the protein MUC1, and setting them as the target for the immune system. Since 90% of cancerous cells display a high concentration of this protein, we can expect that this vaccine will help in treating a majority of the cancer out there, without the additional cost of radiation therapy and its associated risks. Previous research backs up this vaccine, suggesting that it has prompted a potent immunal response in mice as well.
The promising results mean that it is possible that the drug will eventually be human tested and hopefully approved for public use within the next decade. Of course, these are very early stage results, so we can't say for sure that it will work out, but it is nice to hope.